Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-29T17:42:48.290Z Has data issue: false hasContentIssue false
  • English
  • Français

Parkinson's Disease - Levodopa Complications

Published online by Cambridge University Press:  02 December 2014

David B. King
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Parkinson's disease is a readily recognized clinical syndrome, characterized by resting tremor, rigidity, bradykinesia and loss of postural reflexes. The introduction of levodopa transformed our management of this disease. As our experience has increased the long term side effects of levodopa have become more apparent. Levodopa complications comprise: wearing off, motor fluctuations, and psychiatric complications. The complexity of these clinical phenomena has been worked out with time and is now well-recognized. A number of management strategies can ameliorate these long-term complications. This article reviews the current management of late-stage Parkinson's disease.

Résumé

RÉSUMÉ

La maladie de Parkinson est un syndrome clinique facilement reconnaissable, caracterise par un tremblement de repos, de la rigidite, de la bradyk-inesie et une perte des reflexes posturaux. L'introduction de la levodopa a transforme le traitement de cette maladie. Avec l'experience, les effets secondaires a long terme de la levodopa sont devenus plus evidents. Les complications du traitement par la levodopa incluent: l'epuisement de l'effet en fin de dose, les fluctuations motrices et les com-plications psychiatriques. La complexite de ces phenomenes cliniques est maintenant mieux comprise et mieux reconnue. Certaines strategies therapeutiques peuvent ameliorer ces complications du traitement a long terme. Cet article revoit le traitement de la maladie de Parkinson en phase avancee.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 26 , Issue S2 , August 1999 , pp. S13 - S20
Copyright
Copyright © The Canadian Journal of Neurological 1999

References

1. Cotzias, GC, Papavasiliou, PS, Gellene, R. Modification of Parkinsonism – chronic treatment with L-dopa. N Engl J Med 1969: 280: 337–345.CrossRefGoogle ScholarPubMed
2. Stern, MB. Contemporary approaches to the pharmacotherapeutic management of Parkinson’s disease: an overview. Neurology 1997; 49 (Suppl 1): S1-S9.CrossRefGoogle Scholar
3. Marsden, CD. Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 672–681.CrossRefGoogle ScholarPubMed
4. Block, G, et al. Sinemet-CR first, Eur Neurol 1997: 37: 93–97.Google ScholarPubMed
5. Miyawaki, E, Lyons, K, Pahwa, R, Koller, W. Motor complications of chronic levodopa therapy in Parkinson’s disease. Clin Neuropharmacol 1997; 20: 523–530.CrossRefGoogle ScholarPubMed
6. Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson’s disease- clinical aspects. In: Marsden, CD, Fahn, S, eds. Movement Disorders. London: Butterworth Scientific, 1981: 96–122.CrossRefGoogle ScholarPubMed
7. Rajput, AH, Fenton, Me, Birdi, S, et al. Is levodopa toxic to human substantia nigra? Mov Disord 1997; 12(5): 634–638.CrossRefGoogle ScholarPubMed
8. Rajput, AH, Utti, R, Rajput, A, Offord, K. Timely levodopa administration prolongs survival in Parkinson’s disease. Parkinsonism Rel Disord 1997; Volume 3: 159–165.CrossRefGoogle ScholarPubMed
9. Agid, Y. Levodopa: is toxicity a myth? Neurology 1998; 50(4): 858–863.CrossRefGoogle ScholarPubMed
10. Rinne, UK. Early combination of bromocritptine and levodopa in the treatment of early Parkinson’s disease: a five year follow-up. Neurology 1987; 37: 826–828.CrossRefGoogle Scholar
11. Fabbrini, G, Juncos, J, Mouradian, MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson’s disease. Ann Neurol 1987; 21: 370–376.CrossRefGoogle ScholarPubMed
12. Shaw, KM, Lees, AJ, Stern, GM. The impact of treatment with levodopa on Parkinson’s disease. QJ Med 1980: 49: 283–293.Google ScholarPubMed
13. Spencer, SE, Wooten, GF. Altered pharmacodynamics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984: 34: 1105–1108.CrossRefGoogle Scholar
14. Leenders, KL, Palmer, AJ, Quinn, N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986: 49: 853–860.CrossRefGoogle ScholarPubMed
15. Fabbrini, G, Mouradian, MM, Juncos, JL, et al. Motor fluctuations in Parkinson’s disease: central pathophysiologic mechanisms. Ann Neurol 1988: 24: 366–371.Google Scholar
16. Stribe, CMH, Kempster, PA, Lees, AJ, et al. Subcutaneous apomorphine in Parkinsonian on-off oscillations. Lancet 1988: 1: 403–406.CrossRefGoogle Scholar
17. Luquin, MR, Scipioni, O, Vaamonde, J, et al. Levodopa-induced dyskinesias in Parkinson’s disease: clinical and pharmacological classification. Mov Disord 1992; 7: 117–124.CrossRefGoogle ScholarPubMed
18. Nausieda, PA, Weiner, WJ, Klawans, HL. Dystonic foot response of Parkinsonism. Arch Neurol 1980: 37: 132–136.CrossRefGoogle ScholarPubMed
19. Stoessl, AJ. Prevention and management of late stage complications in Parkinson’s disease. Can J Neurol Sci 1992; 19: 113–116.CrossRefGoogle ScholarPubMed
20. Narabayashi, H, Nakamura, R. The freezing phenomenon-problems in long-term treatment for Parkinsonism. In: Rose, FC, Capildeo, R, eds. Research Progress in Parkinson’s Disease. Pitman Medical, 1981: 248–253.Google Scholar
21. Quinn, NP. Classification of fluctuations in patients with Parkinson’s disease. Neurology 1998; 51: S25-S29.CrossRefGoogle ScholarPubMed
22. Marsden, CD, Parkes, JD. On-Off effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet 1976: 1: 292–6.CrossRefGoogle ScholarPubMed
23. Delis, D, Direnfeld, L, Alexander, MP, et al. Cognitive fluctuations associated with on-off phenomenon. Neurology 1982: 32: 1049–1052.CrossRefGoogle ScholarPubMed
24. Melamed, E, Zoldan, J, Friedberg, G, et al. Involvement of serotonin in clinical features of Parkinson’s disease and complications of L-dopa therapy. Adv Neurol 1996; 69: 545–550.Google ScholarPubMed
25. Factor, SA, Molho, ES, Podskalny, GD, et al. Parkinson’s disease: drug-induced psychiatric states. Adv Neurol 1995; 65: 115–138.Google ScholarPubMed
26. Inzelberg, R, Kipervasser, S, Korczyn, AD. Auditory hallucinations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 533–535.CrossRefGoogle ScholarPubMed
27. Ebmeier, KP, Calder, SA, Crawford, JR, et al. Dementia in idiopathic Parkinson’s disease: prevalence and realtionship to the symptoms and signs of parkinsonism. Psychol Med 1991; 21: 69–76.CrossRefGoogle Scholar
28. Tison, F, Dartigues, JF, Auriacombe, S, et al. Dementia in Parkinson’s disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45: 705–708.CrossRefGoogle ScholarPubMed
29. Melamed, E, Bitton, V, Zelig, O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology 1986; 36: 100–103.CrossRefGoogle ScholarPubMed
30. Djaldetti, R, Koren, M, Ziv, I, et al. Effect of cisapride on response fluctuations in Parkinson’s disease. Mov Disord 1995; 10: 81–84.CrossRefGoogle ScholarPubMed
31. Verhagen Metman, L, Del Dotto, P, van den Munckhof, P, et al. Amantadine as treatment for dyskinesia and motor fluctuations in Parkinson’s disease. Neurology 1998; 50(5): 1323–1326.CrossRefGoogle ScholarPubMed
32. Giladi, N, Meer, J, Honigman, S. The use of botulinum toxin to treat striatal toes. J Neurol Neurosurg Psychiatry 1994; 57: 659.CrossRefGoogle ScholarPubMed
33. Chana, P, de Marinis, A, Barrientos, N. Letter to the editor. Mov Disord 1997; 12: 608.Google Scholar
34. Yahr, M, Mendoza, M, Moros, D, et al. Treatment of Parkinson’s disease in early and late phases: use of pharmacological agents with special reference to deprenyl (selegiline. Acta Neurol Scand 1983; (Suppl 95): 95–102.CrossRefGoogle ScholarPubMed
35. Lees, AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. Br Med J 1995; 311: 1602–1607.CrossRefGoogle Scholar
36. Thorogood, M, Armstrong, B, Nichols, T, Hollowell, J. Mortality in people taking selegiline: observational study. Br Med J 1998; 317: 252–254.CrossRefGoogle ScholarPubMed
37. Ben-Shlomo, Y, Churchyard, A, Head, J, et al. Investigation by Parkinson’s Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson’s disease: further results of randomised trial and confidential inquiry Br Med J 1998; 316: 1191–1196.CrossRefGoogle Scholar
38. Olanow, CW, Myllyla, VV, Sotaniemi, KA, et al. Effect of selegiline on mortality in patients with Parkinson’s disease: a meta-analysis. Neurology 1998; 51: 825–830.CrossRefGoogle ScholarPubMed
39. Limousin, P, Pollak, P, Pfeffen, JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin Neuropharmacol 1995; 18: 258–265.CrossRefGoogle Scholar
40. Merello, M, Lees, AJ, Webster, R, et al. Effect of entacapone, a peripherally acting COMT inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 186–189.CrossRefGoogle ScholarPubMed
41. Rabey, JM, Treves, TA, Neufeld, NY, Orlov, E, et al. Low-dose cloza-pine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease. Neurology 1995; 45: 432–434.CrossRefGoogle Scholar
42. Rich, SS, Friedman, JH, Ott, BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psych 1995; 56: 556–559.Google ScholarPubMed
43. Zoldan, J, Friedberg, G, Weizman, A, Melamed, E. Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic levodopa therapy in advanced Parkinson’s disease. Adv Neurol 1996; 69: 541–544.Google ScholarPubMed
44. Bastani, B, Parsa, MA. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1998; 10: 216–219.Google Scholar
45. Albanese, A, Maria, G, Bentivoglio, AR. Severe constipation in Parkinson’s disease relieved by botulinum toxin. Mov Disord 1997; 12: 764–766.CrossRefGoogle ScholarPubMed